Method of detecting diseased or damaged tissue with a pH-triggered polypeptide fluorophore composition

Patent metadata

Field	Value
Publication number	US-11738096-B2
Application number	US-201716334734-A
Country	US
Kind code	B2
Filing date	Sep 22, 2017
Priority date	Sep 22, 2016
Publication date	Aug 29, 2023
Grant date	Aug 29, 2023

Abstract

The present subject matter provides compounds, compositions, and methods for identifying, monitoring, treating, and removing diseased tissue. Compounds, compositions, and methods for identifying, monitoring, and detecting circulating fluids such as blood are also provided.

First claim

What is claimed is:

1. A method for detecting diseased or damaged tissue in a subject, comprising:
(a) administering a pH-triggered polypeptide fluorophore composition comprising the structure:

(b) contacting the subject with electromagnetic radiation comprising an excitation wavelength of the fluorophore; and
(c) detecting electromagnetic radiation emitted from the composition, wherein detection of the radiation indicates the presence of the diseased or damaged tissue.

2. The method of claim 1 , wherein the diseased or damaged tissue is cancer tissue or precancerous tissue.

3. The method of claim 2 , wherein the diseased tissue is cancer tissue, and the cancer tissue is in the bladder, a kidney, the prostate, a breast, the head, the neck, the oral cavity, the pancreas, a lung, the liver, the cervix, an ovary, or the brain of the subject.

4. The method of claim 1 , wherein the level of radiation emitted from precancerous tissue or cancer tissue is at least 20% greater than a level of radiation emitted from normal non-cancerous tissue.

5. The method of claim 1 , wherein the diseased or damaged tissue comprises a bodily organ, and wherein said bodily organ comprises a kidney or a urinary bladder.

6. The method of claim 1 , wherein said composition is administered by applying a liquid, powder, or spray comprising said compound to a surface of said subject.

7. The method of claim 6 , wherein said surface comprises a site within the body of said subject that is accessed via surgery.

8. The method of claim 1 , wherein electromagnetic radiation emitted from said composition is detected in vivo.

9. The method of claim 1 , wherein electromagnetic radiation emitted from said composition is detected ex vivo.

10. The method of claim 1 , further comprising surgically removing a cancer or a precancerous cell or tissue identified by step (c).

11. The method of claim 1 , wherein said pH-triggered polypeptide fluorophore composition further comprises a pharmaceutically acceptable carrier.

12. The method of claim 1 , wherein the pH-triggered polypeptide fluorophore composition is administered to the subject Via intravenous administration, intravesical instillation, or intraperitoneal administration.

13. The method of claim 1 , wherein the diseased or damaged tissue is inflamed tissue, ischemic tissue, arthritic tissue, cystic fibrotic tissue, tissue infected with a microorganism, or atherosclerotic tissue.

14. The method of claim 2 , wherein the diseased tissue is cancer tissue, and the cancer tissue is in the upper urinary tract.

Assignees

• Univ Of Rhode Island Board Of Trustees
• Univ Yale

Inventors

• Reshetnyak Yana K
• Andreev Oleg A
• Engelman Donald M

Classifications

• C07K7/06 Primary

  having 5 to 11 amino acids · CPC title

• C07K14/00

  Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof · CPC title

• A61K49/0045

  the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo · CPC title

• A61K49/0019

  characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules · CPC title

• A61K49/0056 Primary

  Peptides, proteins, polyamino acids · CPC title